Get the Stockscreener App
18.88
3.82%
-0.75
After Hours:
18.98
0.10
+0.53%
Omeros Corp stock is traded at $18.88, with a volume of 993.87K.
It is down -3.82% in the last 24 hours and up +3.28% over the past month.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
See More
Previous Close:
$19.63
Open:
$19.5
24h Volume:
993.87K
Relative Volume:
0.99
Market Cap:
$1.37B
Revenue:
$9.89M
Net Income/Loss:
$84.01M
P/E Ratio:
22.06
EPS:
0.856
Net Cash Flow:
$-101.16M
1W Performance:
+2.00%
1M Performance:
+3.28%
6M Performance:
+65.91%
1Y Performance:
+350.60%
1-Day Range:
$18.83
$19.78
1-Week Range:
$18.02
$20.24
52-Week Range:
$4.055
$21.24
Omeros Corp Stock (OMER) Company Profile
Name
Omeros Corp
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
18.88 | 1.37B | 9.89M | 84.01M | -101.16M | 0.856 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corp Stock (OMER) Latest News
Omeros (OMER) Institutional Ownership 2026 - MarketBeat
Cantor Fitzgerald upgraded Omeros to Overweight for Omeros stock - AD HOC NEWS
Avoiding Lag: Real-Time Signals in (OMER) Movement - Stock Traders Daily
OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug - Stocktwits
Omeros Corporation stock fell 2.06 percent as Yartemlea gains traction - AD HOC NEWS
Omeros (OMER) Stock Looks Cheap After Its Huge Three Year Run - Simply Wall Street
ETFs Investing in Omeros Corporation Stocks - TradingView
Total operating expenses of Omeros Corporation – HAN:3O8 - TradingView
Omeros Corporation stock falls 3.28 percent while analysts target USD 22.00 - AD HOC NEWS
Trading the Move, Not the Narrative: (OMER) Edition - Stock Traders Daily
Form 144 OMEROS CORPORATION For: 26 September By Investing.com - Investing.com Nigeria
Form 144 OMEROS CORPORATION For: 26 September By Investing.com - Investing.com Australia
Press Releases about Omeros CorporationCommon Stock (Nasdaq:OMER) - financialcontent.com
Form 4 Omeros Corporation For: 24 September By Investing.com - Investing.com South Africa
Form 4 Omeros Corporation For: 24 September By Investing.com - Investing.com Nigeria
Omeros VP finance David Borges sells $419,000 in shares By Investing.com - Investing.com Canada
Omeros VP finance David Borges sells $419,000 in shares - Investing.com India
Omeros (OMER) finance VP exercised options and sold shares at $20.95 apiece under a trading plan. - Stock Titan
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights - Stocktwits
The Option Play Of The Week (NASDAQ:OMER) - Seeking Alpha
Omeros stock slips 1.47 percent after Cantor upgrade - AD HOC NEWS
Stock options are the source of shares in officer David Borges's proposed Omeros (OMER) sale. - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Omeros (NASDAQ: OMER) officer to sell 10,000 shares via option exercise - Stock Titan
Omeros Corp (OMER) Hits 52-Week High as Cantor Fitzgerald Upgrades on Yartemlea Sales Outlook - GuruFocus
Omeros Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com
Omeros Shares Rise After Cantor Fitzgerald Upgrade - Yahoo Finance
Omeros stock upgraded at Cantor Fitzgerald (OMER:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Upgrades Omeros (OMER) to Overweight on Strong Yartemlea Launch - GuruFocus
Omeros Corporation stock hits 52-week high at 19.75 USD - Investing.com
OMER Upgraded by Cantor Fitzgerald -- Rating Raised to Overweigh - GuruFocus
Cantor Fitzgerald upgrades Omeros stock rating on Yartemlea launch - Investing.com
Omeros (NasdaqGM:OMER) Stock Forecast & Analyst Predictions - Simply Wall Street
Omeros Stock Price Forecast. Should You Buy OMER? - StockInvest.us
Omeros Corporation (OMER) Slides 4.49% to $18.52, Drifting Toward Key SupportKAMA Signal - careplusvn.com
Omeros Corp VP and General Counsel Peter B. Cancelmo Executes Stock Option Exercises and Sells Shares - Kalkine Media
Omeros Insider Sold Shares Worth $929,668, According to a Recent SEC Filing - marketscreener.com
Omeros VP, finance & CAO David Borges sells $206,804 in shares By Investing.com - Investing.com South Africa
Omeros VP, finance & CAO David Borges sells $206,804 in shares - Investing.com Nigeria
Omeros VP, finance & CAO David Borges sells $206,804 in shares - Investing.com Australia
Omeros VP, finance & CAO David Borges sells $206,804 in shares - Investing.com
Omeros VP, finance & CAO David Borges sells $206,804 in shares - Investing.com India
Omeros VP, finance & CAO David Borges sells $206,804 in shares - Investing.com Canada
Omeros VP, finance & CAO David Borges sells $206,804 in shares - Investing.com UK
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Omeros VP of finance David Borges sells $206,804 in shares By Investing.com - Investing.com Nigeria
Omeros VP of finance David Borges sells $206,804 in shares By Investing.com - Investing.com Canada
Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Omeros VP of finance David Borges sells $206,804 in shares - investing.com
Omeros Corp (OMER) Director Thomas Cable Sells 15,000 Shares - GuruFocus
Omeros Corp Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omeros Corp Stock (OMER) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Borges David J. | VP, Finance & CAO |
Sep 23 '26 |
Sale |
20.95 |
10,000 |
209,500 |
0 |
| DAVID BORGES | Officer |
Sep 23 '26 |
Proposed Sale |
21.05 |
14,927 |
314,213 |
0 |
| Borges David J. | VP, Finance & CAO |
Sep 22 '26 |
Sale |
20.95 |
10,000 |
209,500 |
0 |
| Borges David J. | VP, Finance & CAO |
Sep 22 '26 |
Option Exercise |
3.44 |
10,000 |
34,350 |
10,000 |
| DAVID BORGES | Officer |
Sep 22 '26 |
Proposed Sale |
18.49 |
10,000 |
184,900 |
0 |
| PETER CANCELMO | Officer |
Aug 31 '26 |
Proposed Sale |
18.54 |
25,000 |
463,540 |
0 |
| Cancelmo Peter B | VP, General Counsel |
Aug 31 '26 |
Sale |
18.54 |
25,000 |
463,540 |
200 |
| Cancelmo Peter B | VP, General Counsel |
Aug 28 '26 |
Option Exercise |
2.94 |
25,000 |
73,500 |
25,200 |
| PETER CANCELMO | Officer |
Aug 28 '26 |
Proposed Sale |
18.65 |
25,000 |
466,128 |
0 |
| Cancelmo Peter B | VP, General Counsel |
Aug 28 '26 |
Sale |
18.65 |
25,000 |
466,128 |
200 |
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):